Metformin regulates hepatic lipid metabolism through activating AMP-activated protein kinase and inducing ATGL in laying hens

Wei Lu Chen, Hen Wei Wei, Wen Zan Chiu, Ching Hui Kang, Ting Han Lin, Chien Ching Hung, Ming Chun Chen, Ming Song Shieh, Chin Cheng Lee, Horng Mo Lee

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Although many clinical trials have showed that metformin improves non-alcoholic fatty liver disease, which is a common liver disease associated with hepatic enzyme abnormalities, an animal model is required to investigate the effects of altered gene expression and post-translational processing (proteins) in mediating the observed responses. Laying hens appear to develop fatty livers, as in the case in human beings, when ingesting energy in excess of maintenance, and they can be used as an animal model for observing hepatic steatosis. The aim of this study was to investigate whether metformin could improve the non-alcoholic fatty liver of laying hens and to examine the possible mechanisms of lipid-lowering effects. Forty-eight Leghorn laying hens of Hy-Line variety W-36 - 44 weeks with 64.8% hen-day egg production - were randomly assigned into 4 treatments, each receiving 0, 10, 30, or 100 mg of metformin with saline per kg body weight by daily wing vein injection. Results showed that, compared with the control, significant decreases existed in the laying rates; plasma triglyceride, cholesterol, and insulin levels; body weights; abdominal fat weights; hepatic lipid contents; and hepatic fatty acid synthase expression of layers receiving 30 or 100 mg per kg body weight, whereas significant increases in their hepatic 5′adenosine monophosphate- activated protein kinase, acyl-CoA carboxylase phosphorylation, adipose triglyceride lipase, and carnitine palmitoyl transferase-1 expression were observed. These data suggest that metformin could reduce lipid deposits in the liver and that the laying hen is a valuable animal model for studying hepatic steatosis.

Original languageEnglish
Pages (from-to)107-112
Number of pages6
JournalEuropean Journal of Pharmacology
Volume671
Issue number1-3
DOIs
Publication statusPublished - Dec 5 2011

Fingerprint

AMP-Activated Protein Kinases
Metformin
Lipid Metabolism
Liver
Animal Models
Body Weight
Fatty Liver
Lipids
Fatty Acid Synthases
Abdominal Fat
Carnitine
Post Translational Protein Processing
Transferases
Lipase
Protein Kinases
Ovum
Liver Diseases
Veins
Triglycerides
Cholesterol

Keywords

  • Adipose triglyceride lipase
  • AMP-activated protein kinase
  • Laying hen
  • Metformin
  • Non-alcoholic fatty liver disease

ASJC Scopus subject areas

  • Pharmacology

Cite this

Metformin regulates hepatic lipid metabolism through activating AMP-activated protein kinase and inducing ATGL in laying hens. / Chen, Wei Lu; Wei, Hen Wei; Chiu, Wen Zan; Kang, Ching Hui; Lin, Ting Han; Hung, Chien Ching; Chen, Ming Chun; Shieh, Ming Song; Lee, Chin Cheng; Lee, Horng Mo.

In: European Journal of Pharmacology, Vol. 671, No. 1-3, 05.12.2011, p. 107-112.

Research output: Contribution to journalArticle

Chen, Wei Lu ; Wei, Hen Wei ; Chiu, Wen Zan ; Kang, Ching Hui ; Lin, Ting Han ; Hung, Chien Ching ; Chen, Ming Chun ; Shieh, Ming Song ; Lee, Chin Cheng ; Lee, Horng Mo. / Metformin regulates hepatic lipid metabolism through activating AMP-activated protein kinase and inducing ATGL in laying hens. In: European Journal of Pharmacology. 2011 ; Vol. 671, No. 1-3. pp. 107-112.
@article{4e8f2d9654a2483a8e9ce97342e1ea7b,
title = "Metformin regulates hepatic lipid metabolism through activating AMP-activated protein kinase and inducing ATGL in laying hens",
abstract = "Although many clinical trials have showed that metformin improves non-alcoholic fatty liver disease, which is a common liver disease associated with hepatic enzyme abnormalities, an animal model is required to investigate the effects of altered gene expression and post-translational processing (proteins) in mediating the observed responses. Laying hens appear to develop fatty livers, as in the case in human beings, when ingesting energy in excess of maintenance, and they can be used as an animal model for observing hepatic steatosis. The aim of this study was to investigate whether metformin could improve the non-alcoholic fatty liver of laying hens and to examine the possible mechanisms of lipid-lowering effects. Forty-eight Leghorn laying hens of Hy-Line variety W-36 - 44 weeks with 64.8{\%} hen-day egg production - were randomly assigned into 4 treatments, each receiving 0, 10, 30, or 100 mg of metformin with saline per kg body weight by daily wing vein injection. Results showed that, compared with the control, significant decreases existed in the laying rates; plasma triglyceride, cholesterol, and insulin levels; body weights; abdominal fat weights; hepatic lipid contents; and hepatic fatty acid synthase expression of layers receiving 30 or 100 mg per kg body weight, whereas significant increases in their hepatic 5′adenosine monophosphate- activated protein kinase, acyl-CoA carboxylase phosphorylation, adipose triglyceride lipase, and carnitine palmitoyl transferase-1 expression were observed. These data suggest that metformin could reduce lipid deposits in the liver and that the laying hen is a valuable animal model for studying hepatic steatosis.",
keywords = "Adipose triglyceride lipase, AMP-activated protein kinase, Laying hen, Metformin, Non-alcoholic fatty liver disease",
author = "Chen, {Wei Lu} and Wei, {Hen Wei} and Chiu, {Wen Zan} and Kang, {Ching Hui} and Lin, {Ting Han} and Hung, {Chien Ching} and Chen, {Ming Chun} and Shieh, {Ming Song} and Lee, {Chin Cheng} and Lee, {Horng Mo}",
year = "2011",
month = "12",
day = "5",
doi = "10.1016/j.ejphar.2011.09.029",
language = "English",
volume = "671",
pages = "107--112",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Metformin regulates hepatic lipid metabolism through activating AMP-activated protein kinase and inducing ATGL in laying hens

AU - Chen, Wei Lu

AU - Wei, Hen Wei

AU - Chiu, Wen Zan

AU - Kang, Ching Hui

AU - Lin, Ting Han

AU - Hung, Chien Ching

AU - Chen, Ming Chun

AU - Shieh, Ming Song

AU - Lee, Chin Cheng

AU - Lee, Horng Mo

PY - 2011/12/5

Y1 - 2011/12/5

N2 - Although many clinical trials have showed that metformin improves non-alcoholic fatty liver disease, which is a common liver disease associated with hepatic enzyme abnormalities, an animal model is required to investigate the effects of altered gene expression and post-translational processing (proteins) in mediating the observed responses. Laying hens appear to develop fatty livers, as in the case in human beings, when ingesting energy in excess of maintenance, and they can be used as an animal model for observing hepatic steatosis. The aim of this study was to investigate whether metformin could improve the non-alcoholic fatty liver of laying hens and to examine the possible mechanisms of lipid-lowering effects. Forty-eight Leghorn laying hens of Hy-Line variety W-36 - 44 weeks with 64.8% hen-day egg production - were randomly assigned into 4 treatments, each receiving 0, 10, 30, or 100 mg of metformin with saline per kg body weight by daily wing vein injection. Results showed that, compared with the control, significant decreases existed in the laying rates; plasma triglyceride, cholesterol, and insulin levels; body weights; abdominal fat weights; hepatic lipid contents; and hepatic fatty acid synthase expression of layers receiving 30 or 100 mg per kg body weight, whereas significant increases in their hepatic 5′adenosine monophosphate- activated protein kinase, acyl-CoA carboxylase phosphorylation, adipose triglyceride lipase, and carnitine palmitoyl transferase-1 expression were observed. These data suggest that metformin could reduce lipid deposits in the liver and that the laying hen is a valuable animal model for studying hepatic steatosis.

AB - Although many clinical trials have showed that metformin improves non-alcoholic fatty liver disease, which is a common liver disease associated with hepatic enzyme abnormalities, an animal model is required to investigate the effects of altered gene expression and post-translational processing (proteins) in mediating the observed responses. Laying hens appear to develop fatty livers, as in the case in human beings, when ingesting energy in excess of maintenance, and they can be used as an animal model for observing hepatic steatosis. The aim of this study was to investigate whether metformin could improve the non-alcoholic fatty liver of laying hens and to examine the possible mechanisms of lipid-lowering effects. Forty-eight Leghorn laying hens of Hy-Line variety W-36 - 44 weeks with 64.8% hen-day egg production - were randomly assigned into 4 treatments, each receiving 0, 10, 30, or 100 mg of metformin with saline per kg body weight by daily wing vein injection. Results showed that, compared with the control, significant decreases existed in the laying rates; plasma triglyceride, cholesterol, and insulin levels; body weights; abdominal fat weights; hepatic lipid contents; and hepatic fatty acid synthase expression of layers receiving 30 or 100 mg per kg body weight, whereas significant increases in their hepatic 5′adenosine monophosphate- activated protein kinase, acyl-CoA carboxylase phosphorylation, adipose triglyceride lipase, and carnitine palmitoyl transferase-1 expression were observed. These data suggest that metformin could reduce lipid deposits in the liver and that the laying hen is a valuable animal model for studying hepatic steatosis.

KW - Adipose triglyceride lipase

KW - AMP-activated protein kinase

KW - Laying hen

KW - Metformin

KW - Non-alcoholic fatty liver disease

UR - http://www.scopus.com/inward/record.url?scp=80455143636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80455143636&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2011.09.029

DO - 10.1016/j.ejphar.2011.09.029

M3 - Article

VL - 671

SP - 107

EP - 112

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -